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Randomized clinical trials are considered to be the gold standard of evidence-based medicine nowadays. However,
it is important that we point out some limitations of randomized clinical trials relating to surgical interventions.
There are limitations that affect the external and internal validity of many surgical study designs. Some limitations
can be bypassed, but can make it more difficult for the study to be carried out. Other limitations cannot be
bypassed. When it is intended to extrapolate the result of a randomized clinical trial, the premise is that the
performed or to be performed intervention will be similar wherever applied and/or for every doctor using it.
However, no matter how standardized the technique may be, the results are not similar for all surgeons, which
implies a significant limitation to surgical randomized clinical trials concerning external validity. When considering
the various limitations presented for performing surgical trials capable of generating scientific evidence within the
patterns currently proposed in the evidence level classifications of medical publications, it is necessary to rethink
whether those scientific evidence levels are similarly applicable to surgical works and to nonsurgical trials. We
currently live in a time of supposed ‘‘inferiority’’ of surgical scientific works under the optics of the current quality
criteria for a ‘‘suitable’’ clinical trial.
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Randomized clinical trials are nowadays considered
the gold standard of evidence-based medicine.1
Clinical trials aim at creating subsidies to ground the
use of one or other therapeutic by means of analysis
of different interventions (for instance, medications),
or comparing interventions with placebos.2,3 In
their essence, the scope of clinical trials is to create
scientific evidence to direct medical conduct.4
Displaying internal and external validity is a condition for
the clinical trial to have potential to suggest that a given
therapeutic is the best indicated one. Internal validity
presupposes that the work design be suitable to answer
the question posed by the study. External validity, in turn,
implies the potential of the trial results to be extrapolated to
other populations (being valid not only for the survey
participants). Displaying internal validity is a sine qua non
condition to display external validity, that is methodological
problems affecting the study itself do not allow its results to
be extrapolated.5
Therefore, it is important that we point out some
limitations displayed by randomized clinical trials relating
to surgical interventions,6 limitations that affect the external
and internal validity of many surgical studies designs.7
– Adherence of participants: the random selection of
patients in distinct surgical treatment groups implies
lower patient adherence than clinical studies. In cases of
different surgical interventions in each group or in
comparisons with nonsurgical treatment, this adherence
is even lower. Randomization itself is not attractive to
patients, and is less attractive in surgical trials; for
patients it is easier not to know which medication will be
prescribed to them than not to know the type of surgery
that will be performed on them.
– Feasibility of both groups: the random selection of
patients requires that both surgical techniques can be
performed in compliance with the selection. Any limita-
tion to the performance of one of the techniques (in a
given week, the surgeon’s determination, etc.) implies a
risk of limiting the selection. For instance, in cases of
urgency or trauma the selections can be limited when
both techniques are not performed by all participating
doctors.
– Randomization-based data analysis: in a clinical trial it is
suggested to perform the obtained data analysis based on
the group to which the patient was selected, a principle
named ‘‘intention to treat analysis’’.8,9 In surgical trials,
following this principle can generate strange or even
incongruent responses. For instance, a patient assigned a
nonsurgical treatment who due to whatever reason
receives the surgical treatment, following the intention-
to-treatment principle, should be analyzed as nonsurgi-
cal. If this patient displayed an infection at the surgery
site, we would have a ‘‘surgical site infection occurrence’’
as a ‘‘nonsurgical treatment complication’’ in the results.
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Therefore, the application of this intention-to-treat
principle, which aims at ensuring sample randomization
(and homogenization among the groups), displays
serious limitations in the surgical area.
– Need for a longer interval between randomization and
intervention: drug treatment randomization can be
carried out beforehand, considered ideal, or upon meet-
ing the patient (‘‘flip of a coin’’), considered simpler. In
surgical works, depending on specific instruments or
preparations (such as orthopedic implants) before the
surgery, randomization must necessarily precede the
intervention by a significant time interval.
As to methodology, surgical trials display greater difficulty
instituting ‘‘blinding’’ of the patients and examiners.10–12
Some limitations can be bypassed13 but make it more
difficult for the study to be carried out. Examples of surgical
interventions that limit study ‘‘blinding’’ are provided
below:
– the type of scar displayed (and the absence of scar in
nonsurgical groups)
– other detectable differences, such as radiographs in
orthopedic implant cases
– ‘‘clues’’ that indicate the performed treatment, such as
the day of surgery or the surgeon’s name, when a
particular technique is performed only by one doctor.
– different types of rehabilitation or aspects of postopera-
tive care.
– the assessment or part of the data collection depends on
the surgeon themselves (operatory bleeding data, sur-
gery time, diagnosis of complications)
– diverse medical procedures to be followed in the post-
operative period depend on the doctor knowing a
patient’s intervention. This limits the blinding of the
doctor assisting the patient, and therefore makes it more
troublesome to blind the study.
In the study design, the choice of a surgical trial control
group also displays limitations. In surgical trials the
intervention is permanent, it is not possible to use the
patient as their own control for two consecutive interven-
tions in cases involving single organs. In cases of two organs
(surgery in both eyes or in both knees), at the time of the
second intervention the patient is not the same as at the time
of the first, because of progress due to the first intervention.
In other words, it is not possible to perform a crossover-type
design. Besides, it is convenient to highlight that the use of
placebo groups in surgical trials frequently presents
important ethical limitations.14–16
When it is intended to extrapolate a clinical trial result,
the premise is that the performed or to be performed
intervention (for which the existence of scientific evidence
will be sustained) will be similar for the entire institution or
for all doctors. Thus, we consider that a given medication
will have similar effects if prescribed by different doctors at
different places. This is because the drug and the drug
action mechanism are the same independently of who
prescribes it.
Can this be valid in surgical trials?
Often in surgical trials the intervention performed by a
surgeon is not necessarily identical to that performed by
another surgeon. That is, no matter how reproducible the
technique is, it is not identical. Besides, in general, new
surgical techniques depend on a learning curve, a curve that
can vary for each technique and for each surgeon. This means
that even for the same surgeon, surgeries performed at
different points of the learning curve can substantially differ.
In this sense, the results of a surgical technique obtained
by particular authors can be very different from those
obtained by other authors, without implying methodologi-
cal failures or a chance effect, but instead because the
interventions are not the same.
Using a culinary example, no matter how familiar a recipe
is, the taste will not necessarily be the same when prepared
by several different chefs. The recipe is the same, but the
result is quite different. This is also true in surgical activity.
No matter how standardized the technique may be, the
result is not similar for all surgeons. This phenomenon
implies a significant limitation to the external validity of
surgical works, particularly for those performed by small
groups of surgeons.
Another important limitation frequently presented by
surgical trials consists in the restricted number of cases
studied and the consequent implication on the statistical
power of the work. The power of a study depends on the
sample size, sample homogeneity, homogeneity of results
(standard deviation of the results) and on the difference
among the result averages for each group. Frequently in
surgical studies the number of patients (sample size) is
lower than the minimum required to achieve an 80%
statistical power, a percentage considered as the minimum
acceptable in most clinical trials.17
In view of that, multicenter studies are often proposed, to
expand the number of individuals to be included. Again,
intervention standardization bias is encountered. It is
difficult to state that the surgical intervention performed
in various centers is the same as there is surgeon variability
and inclusion of innumerous other variables that influence
this. For example, the type of anesthesia, different anesthetic
and surgical equipment, the method of sterilizing surgical
materials, the nursing team’s expertise in postoperative
care, organization of the surgical center team (influencing
surgery times), the availability of different technologies
(such as the quality of equipment, e.g. radioscope, micro-
scope) and the different hospital bacterial flora are among
several other factors (detectable and undetectable) that
influence the surgical procedure. It can even be argued that
these biases influence both arms of the work and their effect
will be diluted with increasing numbers of individuals. This
may be true in some cases; however, it can generate a
contrary effect in others, when a given factor causes a bias in
only one of the arms (radioscopy use, when necessary in
only one of the surgical techniques, for instance). Besides, in
the cases in which the increase in the number of individuals
can dilute this variance the study will then require a huge
sample, rendering a study impracticable from financial and
medical viewpoints.
Thus, it becomes necessary to rethink whether those
scientific evidence levels are similarly applicable to surgical
works and to nonsurgical trials, when considering the
various limitations of surgical trials7,18 capable of generating
scientific evidence within the evidence level classifications
currently proposed in medical publications.
Perhaps we should rethink the valorization currently
granted to knowledge derived from case series and opera-
tory techniques and opinions from specialists in surgical
areas.19 Or even ask the question: Are randomized clinical
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trials actually the design for bringing a higher level of
evidence to surgical trials? Along this same line, it should be
discussed: Are the publication acceptance criteria for a
surgical scientific work the same as for clinical works?
At the current scientific moment, it is urgent to reflect on
the direction that medical research in surgical areas should
take. We currently live at a time of supposed ‘‘inferiority’’ of
surgical scientific works under the optics of the current
quality criteria for a ‘‘suitable’’ clinical trial.18,20,21
Besides, this reflection is fundamental, as it reflects not
only on how the clinical trials already published or to be
published must be viewed, but also on other scientific
articles derived therefrom, such as systematic reviews,
currently acclaimed as a high level of scientific evidence.
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